Copies of letters sent to healthcare professionals in June 2013, to inform of new safety information and advice.
|
Date sent |
Medicine |
Safety information |
|---|---|---|
|
13 June 2013 |
Dianette and all cyproterone acetate 2mg/ethinylestradiol 35 mcg products |
Strengthening of warnings, new contraindications, and updated indication |
| 19 June 2013 |
Revlimid (lenalidomide) |
Information to support safe use, including pregnancy-prevention measures |
|
20 June 2013 |
Sublimaze (fentanyl) |
Risk of serotonin syndrome with coadministration of serotonergic drugs |
|
24 June 2013 |
Retigabine (Trobalt) |
Treatment may lead to pigment changes of ocular tissues, including retina, and skin, lips, or nails. Restricted use to adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated |
See also MHRA letter for healthcare professionals sent (external link) on June 27, 2013, regarding the suspension of licences for hydroxyethyl starch products.